Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study-Reference-Cited by-同舟云学术

Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Published:2016-10-06 Issue:2 Volume:160 Page:305-312
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Tolaney Sara M.,Nechushtan Hovav,Ron Ilan-Gil,Schöffski Patrick,Awada Ahmad,Yasenchak Chris A.,Laird A. Douglas,O’Keeffe Bridget,Shapiro Geoffrey I.,Winer Eric P.

Funder

Exelixis

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-4001-y.pdf

Reference24 articles.

1. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10(12):2298–2308. doi: 10.1158/1535-7163.MCT-11-0264

2. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12(2):89–103. doi: 10.1038/nrc3205

3. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR Jr (2013) Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7–15. doi: 10.1002/cncr.27608

4. Parr C, Watkins G, Mansel RE, Jiang WG (2004) The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10(1 Pt 1):202–211

5. Zagouri F, Bago-Horvath Z, Rossler F, Brandstetter A, Bartsch R, Papadimitriou CA, Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A, Dimopoulos MA, Filipits M (2013) High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 108(5):1100–1105. doi: 10.1038/bjc.2013.31

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. REThinking the role of the RET oncogene in breast cancer;Frontiers in Oncology;2024-08-01

2. Recent progress of small-molecule of RET inhibitors against Non-small cell lung cancer;AAPS Open;2024-06-17

3. Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines;Biomedicines;2023-08-28

4. Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model;International Immunopharmacology;2022-12

5. Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation;Future Oncology;2022-06